Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Purpose
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
Eligibility
- Eligible Ages
- Over 65 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 0: This bone marrow or peripheral blood submission to Adaptive is mandatory
prior to registration/randomization for real-time identification of the clone needed
for MRD testing. The bone marrow sample should be from the first aspiration (i.e.,
first pull). Aspirate needle should be redirected if needed to get first pull bone
marrow aspirate. It should be obtained as soon after pre-registration as possible to
confirm registration eligibility
- STEP 0: Patients must be diagnosed with CLL/SLL according to International Workshop
on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria that includes all of the
following:
- ≥ 5 x10^9 /L B lymphocytes (5000/μL) in the peripheral blood (CLL) or a lymph
node biopsy demonstrating SLL with the below immunophenotype (SLL)
- On morphologic review, the leukemic cells must be small mature lymphocytes
- Immunophenotype of CLL cells (performed locally) must reveal a clonal B-cell
population, which coexpress the B cell surface markers of CD19 and CD20, as
well as the T-cell antigen CD5. Patients with bright surface immunoglobulin
expression or lack of CD23 expression in > 10% of cells must lack t(11;14)
translocation by interphase cytogenetics
- STEP 0: Patients must meet criteria for treatment as defined by IWCLL 2018
guidelines which includes at least one of the following criteria:
- Evidence of marrow failure as manifested by the development or worsening of
anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or
thrombocytopenia), typically hemoglobin (Hb) < 10 g/dL, platelet count <
100,000/mm^3
- Massive (> 6 cm below the costal margin), progressive or symptomatic
splenomegaly
- Massive nodes (ie, > 10 cm in longest diameter) or progressive or symptomatic
lymphadenopathy
- Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard
therapy
- Constitutional symptoms, which include any of the following:
- Unintentional weight loss of ≥ 10% within the previous 6 months
- Significant fatigue (ie. Eastern Cooperative Oncology Group [ECOG]
performance status [PS] ≥ 2)
- Fevers >100.5 °F or 38.0°C for 2 weeks or more without evidence of
infection
- Night sweats > 1 month without evidence of infection
- STEP 0: Patients must not have had prior therapy for CLL (except palliative steroids
or treatment of autoimmune complications of CLL with rituximab or steroids)
- STEP 0: Treatment with rituximab and/or high-dose corticosteroids for autoimmune
complications of CLL must be completed prior to enrollment. Palliative steroids must
be at a dose not higher than 20 mg/day of prednisone or equivalent corticosteroid at
the time of registration
- STEP 0: Age ≥ 65 years
- STEP 0: ECOG performance status ≤ 2
- STEP 0: Patients with known HIV infection on effective anti-retroviral therapy with
undetectable viral load within 6 months prior to registration are eligible for this
trial
- STEP 0: For patients with evidence of chronic hepatitis B virus (HBV) infection, the
HBV viral load must be undetectable on suppressive therapy, if indicated
- STEP 0: Patients with a history of hepatitis C virus (HCV), infection must have been
treated and cured. For patients with HCV infection who are currently on treatment,
they are eligible if they have an undetectable HCV viral load
- STEP 0: Patients must not be receiving active systemic anticoagulation with
warfarin. Patients must be off warfarin therapy for at least 5 half-lives washout
and with normal INR prior to enrollment
- STEP 0: Patients with known history or current symptoms of cardiac disease, or
history of treatment with cardiotoxic agents, should have a clinical risk assessment
of cardiac function using the New York Heart Association Functional Classification.
To be eligible for this trial, patients must be class 2B or better.
Patients with acute cardiac events within 6 months prior to registration should be
carefully evaluated for their suitability for enrollment
- STEP 0: No patients with a history of a severe bleeding disorder or a history of
hemorrhagic stroke or intracranial hemorrhage
- STEP 0: No patients with known active progressive central nervous system (CNS)
disease
- STEP 0: No known medical condition causing an inability to swallow oral formulations
of agents
- STEP 1: The adaptive report confirming a measurable and trackable B cell clone
- STEP 1: Patients may not have had major surgery within 7 days of enrollment, or
minor surgery within 5 days of enrollment. Examples of minor surgery include dental
surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint.
The decision about whether a surgery is major or minor can be made at the discretion
of the treating physician
- STEP 1: No patients with ongoing active fungal, bacterial or viral infection
requiring systemic therapy except those described in the protocol document
- STEP 1: Patients must not require more than 20 mg prednisone or equivalent
corticosteroid daily
- STEP 1: Patients must not have uncontrolled active systemic infection requiring
intravenous antibiotics
- STEP 1: Patients must not have continued requirement for therapy with a strong
CYP3A4/5 inhibitor or inducer. Any such inhibitor or inducer must have been
discontinued at least 14 days or 5 half-lives (whichever is shorter) before the
first dose of study drug
- STEP 1: Absolute neutrophil count (ANC) ≥ 1,000/mm3 unless due to marrow involvement
- STEP 1: Platelet count ≥ 30,000/mm3
- STEP 1: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless due to liver
involvement, hemolysis or Gilbert's disease)
- STEP 1: Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
[SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT])
≤ 3.0 x upper limit of normal (ULN) unless due to disease infiltration of the liver
- STEP 1: Calculated (calc.) creatinine clearance by Chronic Kidney Disease
Epidemiology Collaboration equation (CKD-EPI) ≥ 30 mL/min
- STEP 1: Urine protein to creatinine ratio < 1 or urine protein ≤ 1+
- STEP 2: Detectable MRD ≥ 10 residual clonal cells per million nucleated cells in
peripheral blood at the C15 restaging evaluation from ClonoSEQ
- STEP 2: Response of PR, PR-L, CR, CCR or CRi to zanubrutinib sonrotoclax therapy
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm 1 (zanubrutinib) |
Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study. |
|
|
Experimental Arm 2 (zanubrutinib and sonrotoclax) |
Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, PR-L, CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C. ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity. ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection |
|
Recruiting Locations
Los Angeles, California 90048
Jupiter, Florida 33458
Boise, Idaho 83706
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60611
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
Normal, Illinois 61761
Normal, Illinois 61761
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Washington, Illinois 61571
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Carroll, Iowa 51401
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Pella, Iowa 50219
Waukee, Iowa 50263
Site Public Contact
515-241-3305
Chanute, Kansas 66720
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Independence, Kansas 67301
Kansas City, Kansas 66160
Kingman, Kansas 67068
Liberal, Kansas 67905
McPherson, Kansas 67460
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66210
Parsons, Kansas 67357
Pratt, Kansas 67124
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Louisville, Kentucky 40245
Brighton, Michigan 48114
Canton, Michigan 48188
Chelsea, Michigan 48118
Lansing, Michigan 48912
Livonia, Michigan 48154
Pontiac, Michigan 48341
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55407
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
St Louis, Missouri 63110
St Louis, Missouri 63129
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63136
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Cherry Hill, New Jersey 08002
Sewell, New Jersey 08080
Rochester, New York 14642
Site Public Contact
585-275-5830
Webster, New York 14580
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Hendersonville, North Carolina 28791
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Columbus, Ohio 43210
Oklahoma City, Oklahoma 73104
Baker City, Oregon 97814
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Yankton, South Dakota 57078
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Edmonds, Washington 98026
Issaquah, Washington 98029
Seattle, Washington 98122
Ashland, Wisconsin 54806
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
La Crosse, Wisconsin 54601
Madison, Wisconsin 53705
Site Public Contact
608-256-1901
Mukwonago, Wisconsin 53149
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Sturgeon Bay, Wisconsin 54235-1495
Waukesha, Wisconsin 53188
More Details
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To compare the progression free survival (PFS) between minimal residual disease (MRD)-guided zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control. II. To determine the PFS comparing fixed duration zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control. SECONDARY OBJECTIVES: I. To compare the PFS between the patients with MRD-detectable disease treated with fixed duration zanubrutinib sonrotoclax to the PFS of the patients with MRD detectable disease who receive one additional year of combination therapy. II. To determine the overall survival of all arms of the study. III. To determine the frequency of patients with MRD-detectable disease who convert to undetectable MRD, and at what depth and for how long, after receiving an extra year of combination therapy on the MRD-guided zanubrutinib sonrotoclax therapy arm. IV. To determine and compare the overall response rate (ORR defined as PR, CR, CCR, CRi) and complete remission rate (CR) after 14 cycles of therapy among the three arms. V. To compare time to the next CLL/SLL therapy among treatment arms. VI. To determine the rates and severity of toxicity in each arm, with a particular focus on adverse events of special interest that include infections, cardiovascular events (arrhythmias, heart failure, hypertension), tumor lysis syndrome, bleeding events, cytopenias, and second malignancies. VII. To compare patient-reported symptomatic adverse events as assessed by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) between arms 1 and 2. EXPLORATORY OBJECTIVES: I. To compare the best achieved rate of undetectable MRD (uMRD) between the fixed duration zanubrutinib sonrotoclax arm and the MRD guided zanubrutinib sonrotoclax arm. II. To compare rates of undetectable MRD measured by the immunoglobulin heavy chain (IGH) sequencing assay ClonoSeq (sensitivity 1 in 10^-6) to undetectable MRD measured by standard six-color flow cytometry (uMRD4), and to compare results from bone marrow to peripheral blood. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo computed tomography (CT) scan, bone marrow aspiration and blood sample collection throughout the study. ARM 2: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, partial response with persistent lymphocytosis (PR-L), CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C. ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity. ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for 3 years then every 6 months until 10 years for study registration. Patients with progression or the start of non protocol CLL directed therapy are followed every 6 months for 10 years from registration.